Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02160626 | Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis | PHASE2 | COMPLETED | 172 | — | — | Jun 1, 2014 | Dec 1, 2014 | Jan 3, 2019 | 5 | United States |
Mean of per-subject percentages of target lesions judged to be clear on the PLA (PLA = 0) at end of study (Visit 8). The PLA is a four point scale from 0 being clear to 3 being most severe lesion.
| Arm | Type | Description |
|---|---|---|
| A-101 Vehicle | PLACEBO_COMPARATOR | A-101 Vehicle (placebo) Topical Solution |
| A-101 (40) Topical Solution | ACTIVE_COMPARATOR | A-101 (40) Topical Solution - high dose |
| A-101 (32.5) Topical Solution | ACTIVE_COMPARATOR | A-101 (32.5) Topical Solution - low dose |
| Name | Type | Description |
|---|---|---|
| A-101 Vehicle | DRUG | Placebo control |
| A-101 (40) Topical Solution | DRUG | A-101 (40) Topical Solution - high dose |
| A-101 (32.5) Topical Solution | DRUG | A-101 (32.5) Topical Solution - low dose |
Inclusion Criteria: 1. Subject is at least 18 years of age 2. Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis 3. Subject has 4 appropriate seborrheic keratosis target lesions, as defined below, on the trunk/extremities: * Have a clinically typical appearance ...